Skip to main content
Rafael Bejar, MD, Oncology, La Jolla, CA

RafaelBejarMDPhD

Oncology La Jolla, CA

Hematologic Oncology

Assistant Professor, University of California, San Diego

Dr. Bejar is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Bejar's full profile

Already have an account?

  • Office

    3855 Health Sciences Dr
    # MC0820
    La Jolla, CA 92093
    Phone+1 858-534-5204
    Fax+1 858-246-1847

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2006 - 2011
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2004 - 2006
  • University of Chicago
    University of ChicagoInternship, Internal Medicine, 2003 - 2004
  • University of California San Diego School of Medicine
    University of California San Diego School of MedicineClass of 2003

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2012 - 2026
  • MA State Medical License
    MA State Medical License 2005 - 2014
  • IL State Medical License
    IL State Medical License 2003 - 2006
  • American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • TP53 State Dictates Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes
    Rafael Bejar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Clonal Cytopenias of Undetermined Significance Are Common in Cytopenic Adults Evaluated for MDS in the National MDS Study
    Rafael Bejar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a L... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • DNA Methylation Identifies Genetically and Prognostically Distinct Subtypes of MDS 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Hippo Kinase Inactivation Contributes to Del(20q) Malignancies and Cooperates with JAK2-V617F to Promote Myelofibrosis in Mice 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials
    Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine TrialsDecember 2nd, 2024
  • Aptose Reports Results for the Second Quarter 2022
    Aptose Reports Results for the Second Quarter 2022August 2nd, 2022
  • HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia
    HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid LeukemiaDecember 13th, 2021
  • Join now to see all